3-years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults

European Annals of Allergy and Clinical Immunology

Volumn 44, Issue 3, 2012, Pages 135-140

  Dominicus, R ^a  

^a Medical practice for Allergology Dermatology and Venerology   (Germany)

Author keywords

Adults; Allergoid; Disease modifying effect; Grass pollen; High dose hypoallergenic preparation; Long term effect; Prevention of new sensitizations; Quality of life; Subcutaneous immunotherapy; Symptom medication score

Indexed keywords

ALLERGOVIT; GRASS POLLEN VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GRASS POLLEN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLLEN ALLERGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS IMMUNOTHERAPY; TREATMENT OUTCOME;

ADULT; ANTIGENS, PLANT; AREA UNDER CURVE; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PLANT EXTRACTS; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; YOUNG ADULT;

EID: 84862684125     PISSN: 17641489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005;60:801-7.
2. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82):1-20.
3. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper-Allergen immunotherapy: therapeutic vaccines for allergic diseases-Geneva, January 27-29,1997. Allergy 1998;53(Suppl.44):4-42.
4. Calderon MA, Larenas D, Kleine-Tebbe J, et al. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'. Allergy 2011;66:1345-59.
5. Rolland JM, Gardner LM, O'Hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009;121:273-84.
6. Marsh DG. Preparation and properties of "allergoids" derived from native pollen allergens by mild formalin treatment. Int Arch Allergy 1971;41:199-215.
7. Eng PA, Gnehm HE, Joller-Jemelka H. Klinische und immunogene Wirkung der präsaisonalen Hyposensibilisierung bei Kindern mit Pollinosis. Monatsschr Kinderheilkd 1994;142:616-22.
8. Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C, Kalayci O. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 2006;17:396-407.
9. Tari MG, Mancino M, Ghezzi E, Frank E, Cromwell O. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: A 2-year, double-blind, placebo-controlled study. Allergy 1997;52:65-74.
10. Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999;29:1326-35.
11. Williams A, Henzgen M, Rajakulasingam K. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. Eur Ann Allergy Clin Immunol 2007;39:123-5.
12. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-8.
13. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61:198-201.
14. Eng PA, Reinhold M, Gnehm HE. Long-term efficacy of preseasonal grass-pollen immunotherapy in children. Allergy 2002;57:306-11.
15. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-7.
16. Reha CM, Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol et Immunopathol 2007;35:44-51.
17. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. New Engl J Med 1999;341:468-75.
18. Tahamiler R, Canakcioglu S, Yilmaz S, Isildak H. Long-term immunotherapy for perennial allergic rhinitis: Relationship of specific IgG levels to skin-prick test results and clinical symptoms and signs. Ear Nose Throat J 2008;87:E29-E32.
19. Jacobsen L, Nüchel-Petersen B, Wihl JA, Lowenstein H, Ipsen H, Petersen BN. Immunotherapy with partially purified and standardized tree pollen extracts.4. Results from long-term (6-year) follow-up. Allergy 1997;52:914-20.
20. Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergenspecific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med 2009;103:800-12.
21. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
22. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-3.
23. Plewako H, Holmberg K, Oancea I, Gotlib T, Samolinski B, Rak S. A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa. Clin Exp Allergy 2008;38:1124-31.
24. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 2007;17:85-91.
25. Tella R, Bartra J, San Miguel M, et al. Effects of specific immunotherapy on the development of new sensitisations in monosensitised patients. Allergol et Immunopathol 2003;31:221-5.
26. Asero R. Injection immunotherapy with different airborne allergens did not prevent de novo sensitization to ragweed and birch pollen north of Milan. Int Arch Allergy Appl Immunol 2004;133:49-54.
27. Fasce L, Tosca MA, Olcese R, Milanese M, Erba D, Ciprandi G. The natural history of allergy: the development of new sensitizations in asthmatic children. Immunol Lett 2004;93:45-50.
28. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31:1295-302.
29. Kim KW, Kim EA, Kwon BC, et al. Comparison of allergic indices in monosensitized and polysensitized patients with childhood asthma. J Korean Med Sci 2006;21:1012-6.
30. Loureiro G, Tavares B, Chieira C, Pereira C. Effect of Dermatophagoides specific immunotherapy on cutaneous reactivity. Eur Ann Allergy Clin Immunol 2007;39:5-8.
31. Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008;121:1120-5.
32. Ameal A, Vega-Chicote JM, Fernandez S, et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005;60:1178-83.
33. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-3.
34. Ali I, Goksal K, Ozan B, Gulsen D. Long-term allergen-specific immunotherapy correlates with long-term allergen-specific immunological tolerance. Adv Ther 2008;25:29-36.
35. Frolund L, Durham SR, Calderon M, et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010;65:753-7.
36. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24.